No therapy for ~20 percent with stage IV solid tumors

Share this article:
No Therapy for ~20 Percent With Stage IV Solid Tumors
No Therapy for ~20 Percent With Stage IV Solid Tumors

(HealthDay News) -- About 20 percent of patients diagnosed with stage IV metastatic solid tumors do not receive anticancer treatment, according to a study published online June 15 in Cancer.

Alexander C. Small, of the Mount Sinai School of Medicine in New York City, and associates queried the National Cancer Data Base to identify patients diagnosed with metastatic solid tumors who received neither radiotherapy nor systemic therapy between 2000 and 2008.

The researchers identified 773,233 patients, of whom 20.6 percent received no anticancer treatment. Fifty-five percent of the untreated population was made up of patients with non-small-cell lung cancer. The highest rates of no treatment were seen for patients with cancers of the kidney (25.5 percent) and lung (24 percent), and the lowest rate of no treatment was seen for patients with prostate cancer (11.1 percent). Factors significantly associated with no treatment across all cancer types included older age (prevalence ratio [PR] range, 1.37 to 1.49), black race (PR range, 1.05 to 1.32), lack of medical insurance (PR range, 1.47 to 2.46), and lower income for all cancers except uterine (PR range, 0.91 to 0.98 for every $10,000 increase in income).

"A large percentage of patients presenting with advanced solid tumors at the time of their initial cancer diagnosis receive no anticancer therapy," the authors write. "Further studies are necessary to better define the reasons for this lack of treatment, particularly because these relate to access to care, health literacy, and treatment disparities."

One author disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Statins may lower progression risk for renal cancer

Statins may lower progression risk for renal cancer

Use of statins is associated with a reduced risk of progression of localized renal cell carcinoma, according to research.

Cyramza approved by FDA for stomach cancer

Cyramza approved by FDA for stomach cancer

Cyramza (ramucirumab) has been approved by the U.S. Food and Drug Administration to treat cancer of the stomach.

Cancer patients require anxiety and depression screening

Cancer patients require anxiety and depression screening

It is important to recognize and treat anxiety or depression among cancer patients, according to a clinical guideline published in the Journal of Clinical Oncology.